Exploiting sex-dependent brain injury response for nanoparticle therapeutics
利用性别依赖性脑损伤反应进行纳米颗粒治疗
基本信息
- 批准号:10320959
- 负责人:
- 金额:$ 48.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAgingAmericasArtificial nanoparticlesBacteriophagesBioinformaticsBiologicalBlood - brain barrier anatomyBlood VesselsBrainBrain InjuriesCancer ModelCellsClinical DataClinical PharmacologyComplexCytometryDataDepositionDiseaseDistributional ActivityDrug Delivery SystemsDrug KineticsDrug TargetingEconomic BurdenEncapsulatedEnvironmentEstrogensEventFemaleFunctional disorderGoalsGonadal Steroid HormonesHistone Deacetylase InhibitorHistonesHormonalHormonesHourImmuneInflammationInflammatoryInjuryInterventionIntravenousLabelLeadLigandsLoperamideMediatingMemoryMissionMusNervous System TraumaNeuraxisOutcomePathologicPathologyPatient-Focused OutcomesPersonsPharmaceutical PreparationsPharmacologyPhasePhase III Clinical TrialsProestrusProgesteronePublic HealthPublishingResearchRoleSex DifferencesShapesStrokeSubarachnoid HemorrhageSystemTBI treatmentTestingTherapeuticTight JunctionsTimeTissuesTranslatingTraumatic Brain InjuryTreatment EfficacyUnited States National Institutes of HealthWomen&aposs HealthWorkbasebiological sexblood-brain barrier disruptionblood-brain barrier permeabilizationbrain parenchymacentral nervous system injurycontrolled cortical impactdesigndigitaldrug distributionethylene glycolexperienceimprovedimproved outcomein vivoinhibitorinjuredinjury-related deathinnovationintravital imagingmalemouse modelnanomedicinenanoparticlenanoparticle deliverynanoparticle drugneuroinflammationnext generationnext generation sequencingnovelpoly(lactic acid)pre-clinicalresponseresponse to brain injuryresponse to injurysexside effecttargeted treatmenttherapeutic nanoparticlestranscriptome sequencingtwo photon microscopywater channel
项目摘要
Abstract
Traumatic brain injury (TBI) afflicts over 1.7 million persons per year in the U.S. alone, resulting in
substantial economic burden annually. To date, despite promising pre-clinical data, no new pharmacological
strategies have demonstrated improved patient outcomes in a phase III clinical trial. One significant and often-
overlooked pitfall of pharmacological strategies is the use of systemic administration of free drug, where toxic
and/or negative side effects may limit the therapeutic threshold at tissue targets. Nanoparticles (NPs) have
emerged as an ideal approach to address such drug delivery obstacles. Our long-term goal is to engineer NP
delivery systems to improve outcomes in TBI. Here, we will focus on developing a mechanistic understanding
of sex-dependent differences in pathophysiology that lead to altered NP delivery to the injured brain of male
versus female mice. Our group recently demonstrated that a TBI provides a unique window to deliver NPs to
the parenchyma within both of these BBB disruption events. We discovered a sex-dependent response in BBB
disruption and subsequent NP delivery profiles, whereby the BBB of females remained open for longer and to
a greater extent than males. There is limited understanding of how sex hormones influence TBI induced BBB
disruption over the longer term and the potential impact it has on drug delivery. To address this unmet need,
we will directly examine the influence of sex hormones on TBI pathophysiology and drug delivery, and we will
develop new strategies for targeting sex-dependent injury microenvironments. Our studies will address both
mechanistic and therapeutic goals, focusing on NPs composed of poly(lactic acid)-poly(ethylene glycol) (PLA-
PEG) and loaded with the histone deacetylase inhibitor quisinostat, which we have already shown are
neuroprotective following TBI in mice. We will leverage our existing experience with bacteriophage biopanning
to identify sex-targeting ligands to enhance drug delivery to unique, hormone-dependent post injury
microenvironments. We hypothesize that differences in NP delivery to male and female mice can be attributed
to sex hormone-dependent contributions to TBI pathophysiology, and we predict that improving our
understanding of these sex differences will enable us to design more effective NP delivery systems. We will
probe this central hypothesis through the following specific aims: (1) Investigate the contribution of hormone
mediated sex-dependent injury sequelae on BBB disruption and inflammation, (2) Establish the relationship
between hormone mediated sex-dependent injury, drug delivery, and efficacy, and (3) Demonstrate feasibility
of sex-specific targeting for NP and drug delivery to TBI. Impact from these studies includes deepened
mechanistic understanding of sex-dependent responses to TBI with response to nanoparticle drug delivery, as
well as the first exploration of sex-targeted drug delivery to the brain. This will contribute to a thorough
understanding of the pathophysiology of TBI and more broadly the potential to exploit inherent biological
complexities for developing NP-based drug delivery strategies in context of brain injury.
抽象的
仅在美国,每年就有超过 170 万人遭受创伤性脑损伤 (TBI) 的折磨,导致
每年造成巨大的经济负担。迄今为止,尽管临床前数据有希望,但还没有新的药理学
在 III 期临床试验中,策略已证明可以改善患者的治疗结果。一个重要且经常发生的——
药理学策略被忽视的陷阱是使用游离药物的全身给药,其中有毒
和/或负面副作用可能会限制组织靶点的治疗阈值。纳米颗粒(NP)具有
成为解决此类药物输送障碍的理想方法。我们的长期目标是设计 NP
改善 TBI 治疗效果的输送系统。在这里,我们将重点发展机械理解
病理生理学中性别依赖性差异导致男性受损大脑的 NP 递送改变
与雌性小鼠相比。我们的小组最近证明,TBI 提供了一个独特的窗口来向
这两个 BBB 破坏事件中的实质。我们发现 BBB 存在性别依赖性反应
破坏和随后的 NP 传递曲线,从而使女性的 BBB 保持开放时间更长并
程度比男性更大。对于性激素如何影响 TBI 诱导的 BBB 的了解有限
长期破坏及其对药物输送的潜在影响。为了解决这一未满足的需求,
我们将直接研究性激素对 TBI 病理生理学和药物输送的影响,并且我们将
制定针对性别依赖性损伤微环境的新策略。我们的研究将解决这两个问题
机制和治疗目标,重点关注由聚乳酸-聚乙二醇(PLA-
PEG)并负载组蛋白脱乙酰酶抑制剂 quisinostat,我们已经证明了
小鼠 TBI 后的神经保护作用。我们将利用我们在噬菌体生物淘选方面的现有经验
识别性别靶向配体以增强药物递送到独特的、激素依赖性损伤后
微环境。我们假设雄性和雌性小鼠的 NP 递送差异可归因于
性激素依赖性对 TBI 病理生理学的贡献,我们预测,改善我们的
了解这些性别差异将使我们能够设计更有效的纳米粒子递送系统。我们将
通过以下具体目标探讨这一中心假设:(1)研究激素的贡献
介导的性别依赖性损伤后遗症对 BBB 破坏和炎症的影响,(2)建立关系
激素介导的性依赖性损伤、药物递送和疗效之间的关系,以及 (3) 证明可行性
NP 的性别特异性靶向和 TBI 的药物输送。这些研究的影响包括加深
对 TBI 性别依赖性反应和纳米颗粒药物递送反应的机制理解,如
以及首次探索将性别靶向药物输送到大脑。这将有助于彻底
了解 TBI 的病理生理学以及更广泛地利用固有生物学的潜力
在脑损伤的情况下开发基于 NP 的药物输送策略的复杂性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rachael W Sirianni其他文献
Rachael W Sirianni的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rachael W Sirianni', 18)}}的其他基金
Exploiting sex-dependent brain injury response for nanoparticle therapeutics
利用性别依赖性脑损伤反应进行纳米颗粒治疗
- 批准号:
10532166 - 财政年份:2021
- 资助金额:
$ 48.88万 - 项目类别:
Targeting Leptomeningeal Metastasis in Medulloblastoma
靶向髓母细胞瘤的软脑膜转移
- 批准号:
10829143 - 财政年份:2019
- 资助金额:
$ 48.88万 - 项目类别:
Intrathecal delivery of radiation sensitizing nanoparticles in pediatric neuro-oncology
放射增敏纳米颗粒在儿科神经肿瘤学中的鞘内递送
- 批准号:
10653853 - 财政年份:2019
- 资助金额:
$ 48.88万 - 项目类别:
Targeting leptomeningeal metastasis in medulloblastoma
靶向髓母细胞瘤的软脑膜转移
- 批准号:
10595323 - 财政年份:2019
- 资助金额:
$ 48.88万 - 项目类别:
Intrathecal delivery of radiation sensitizing nanoparticles in pediatric neuro-oncology
放射增敏纳米颗粒在儿科神经肿瘤学中的鞘内递送
- 批准号:
10755398 - 财政年份:2019
- 资助金额:
$ 48.88万 - 项目类别:
Intrathecal delivery of radiation sensitizing nanoparticles in pediatric neuro-oncology
放射增敏纳米颗粒在儿科神经肿瘤学中的鞘内递送
- 批准号:
10200874 - 财政年份:2019
- 资助金额:
$ 48.88万 - 项目类别:
Intrathecal delivery of radiation sensitizing nanoparticles in pediatric neuro-oncology
放射增敏纳米颗粒在儿科神经肿瘤学中的鞘内递送
- 批准号:
9811126 - 财政年份:2019
- 资助金额:
$ 48.88万 - 项目类别:
Targeting leptomeningeal metastasis in medulloblastoma
靶向髓母细胞瘤的软脑膜转移
- 批准号:
9917838 - 财政年份:2019
- 资助金额:
$ 48.88万 - 项目类别:
相似国自然基金
角质形成细胞源性外泌体携载miR-31调控成纤维细胞ERK通路抗皮肤老化的作用机制
- 批准号:82373460
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
塑料光老化介导的微(纳)塑料形成和光解产物释放对雄性生殖内分泌的干扰研究
- 批准号:22376195
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
东北黑土中农膜源微塑料冻融老化特征及其毒性效应
- 批准号:42377282
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
温度作用下CA砂浆非线性老化蠕变性能的多尺度研究
- 批准号:12302265
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
苯乙烯-丁二烯共聚物力化学老化的自由基捕获光环加成协同修复机制
- 批准号:22303065
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Prosthetic Joint Infection After Primary Total Knee Arthroplasty: Incidence, Microbiology and Risk Factors
初次全膝关节置换术后假体关节感染:发生率、微生物学和危险因素
- 批准号:
10463223 - 财政年份:2022
- 资助金额:
$ 48.88万 - 项目类别:
Biological Sciences Program at The Gerontological Society of America's 2022 Annual Scientific Meeting
美国老年学会 2022 年科学年会生物科学项目
- 批准号:
10469163 - 财政年份:2022
- 资助金额:
$ 48.88万 - 项目类别:
Hemostasis, Hematoma Expansion, and Outcomes After Intracerebral Hemorrhage
脑出血后的止血、血肿扩张和结果
- 批准号:
10598712 - 财政年份:2022
- 资助金额:
$ 48.88万 - 项目类别:
Get Experience in Aging Research Undergraduate Program (GEAR UP)
获得衰老研究本科课程(GEAR UP)的经验
- 批准号:
10411181 - 财政年份:2022
- 资助金额:
$ 48.88万 - 项目类别:
Center for Leadership in Environmental Awareness and Research
环境意识和研究领导力中心
- 批准号:
10352961 - 财政年份:2022
- 资助金额:
$ 48.88万 - 项目类别: